Additionally, only in male NASH patients, there was a significant increase in expression of SPTLC2, a subunit of SPT, that regulates its activity and de novo ceramide biosynthesis and contributes to metabolic diseases [9,13,52]. This evidence concerns the gene AGXT and metabolic dysfunction-associated steatohepatitis.